RO 3201195
Alternative Names: RO320-1195Latest Information Update: 04 Jul 2006
At a glance
- Originator Roche Palo Alto LLC
- Developer Roche Palo Alto
- Class Antirheumatics; Pyrazoles; Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 04 Jul 2006 No development reported - Phase-I for Rheumatoid arthritis in USA (unspecified route)
- 27 Sep 2001 Phase-I clinical trials in Rheumatoid arthritis in USA (unspecified route)
- 27 Sep 2001 New profile